Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs

Eur J Cancer. 1994;30A(10):1541-5. doi: 10.1016/0959-8049(94)00287-f.

Abstract

Among human sarcomas, osteosarcomas usually display high intrinsic mdr1 expression while malignant fibrous histiocytomas (MFH) do not. A comparative polymerase chain reaction (PCR)-based sequence analysis of the mdr1 promoter revealed point mutations in seven out of nine osteosarcomas at nucleotides +103 (2 cases T-->C) and +137 (5 cases G-->T). No changes were seen in eight MFHs. When COS cells transfected with CAT constructs containing the T-->C chloramphenicol acetyltransferase mutant mdr1 promoters were treated with vincristine or doxorubicin, expression of the CAT gene was enhanced to a higher extent than with constructs containing wild-type or G-->T-mutant mdr1 promoters. We suggest that there is a correlation between the type of mdr1 promoter mutation and responsiveness to MDR relevant drugs.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Base Sequence
  • Blotting, Northern
  • Bone Neoplasms / genetics*
  • Doxorubicin / pharmacology
  • Drug Resistance, Multiple / genetics*
  • Histiocytoma, Benign Fibrous / genetics
  • Humans
  • Molecular Sequence Data
  • Osteosarcoma / genetics*
  • Point Mutation / physiology*
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics
  • Vincristine / pharmacology

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Vincristine
  • Doxorubicin